BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Clinical Outcome
13 results:

  • 1. TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor clinical outcome?
    Solhusløkk Höse K; Stenman A; Svahn F; Larsson C; Juhlin CC
    Endocr Pathol; 2023 Mar; 34(1):129-141. PubMed ID: 36656469
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas.
    Tufton N; Hearnden RJ; Berney DM; Drake WM; Parvanta L; Chapple JP; Akker SA
    Endocr Relat Cancer; 2022 Nov; 29(11):589-598. PubMed ID: 35975974
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
    Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
    Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
    Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
    Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Kozloff M; Simionato F; Cleverly A; Smith C; Wang S; Man M; Driscoll KE; Estrem ST; Lahn MMF; Benhadji KA; Tabernero J
    Cancer Chemother Pharmacol; 2019 May; 83(5):975-991. PubMed ID: 30887178
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Positive Impact of Genetic Test on the Management and outcome of Patients With Paraganglioma and/or Pheochromocytoma.
    Buffet A; Ben Aim L; Leboulleux S; Drui D; Vezzosi D; Libé R; Ajzenberg C; Bernardeschi D; Cariou B; Chabolle F; Chabre O; Darrouzet V; Delemer B; Desailloud R; Goichot B; Esvant A; Offredo L; Herman P; Laboureau S; Lefebvre H; Pierre P; Raingeard I; Reznik Y; Sadoul JL; Hadoux J; Tabarin A; Tauveron I; Zenaty D; Favier J; Bertherat J; Baudin E; Amar L; Gimenez-Roqueplo AP;
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1109-1118. PubMed ID: 30698717
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
    Gupta S; Zhang J; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. sdhb mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Circulating Chromogranin A as A Marker for Monitoring clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
    PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with sdhb-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
    Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
    Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.
    Gao Y; Liu Z; Chen X; Luo W; Zhang L; Wang J
    BMC Cancer; 2011 Oct; 11():439. PubMed ID: 21989202
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Nov; 2(6):555-60. PubMed ID: 19780299
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.